Peptides: An arrival point in cancer vaccinology

Frontiers in Bioscience - Scholar

Volumn 4 S, Issue 4, 2012, Pages 1381-1392

  Willers, Joerg ^a   Capone, Giovanni ^b   Lucchese, Alberta ^c  

^a CYTOS BIOTECHNOLOGY AG   (Switzerland)

^b UNIVERSITY OF BARI   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Active versus passive immunization; Immunogenic peptides; Low similarity peptides; Peptide based vaccines; Review; Vaccine approaches

Indexed keywords

CANCER VACCINE; IPILIMUMAB; MEMBRANE PROTEIN; PEPTIDE; PEPTIDE VACCINE; POLYSACCHARIDE; RITUXIMAB; SIGNAL PEPTIDE; SMALLPOX VACCINE;

ACTIVE IMMUNIZATION; AMINO ACID SEQUENCE; B LYMPHOCYTE; CANCER IMMUNIZATION; CANCER PREVENTION; CELLULAR IMMUNITY; CONJUGATE; CROSS REACTION; DRUG DESIGN; EFFECTOR CELL; ESCHERICHIA COLI; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; IMMUNOSUPPRESSIVE TREATMENT; NEOPLASM; NONHUMAN; PASSIVE IMMUNIZATION; REVIEW; SMALLPOX; T LYMPHOCYTE; UNSPECIFIED SIDE EFFECT; ANIMAL; AUTOIMMUNITY; IMMUNOLOGY;

ANIMALS; AUTOIMMUNITY; CANCER VACCINES; HUMANS; NEOPLASMS; PEPTIDES;

EID: 84869389230     PISSN: 19450516     EISSN: 19450524     Source Type: Journal    
DOI: None     Document Type: Review

References (138)

1. E Tognotti: The eradication of smallpox, a success story for modern medicine and public health: what lessons for the future? J Infect Dev Ctries 4, 264-266 (2010)
2. SA Plotkin: Vaccines: the fourth century. Clin Vaccine Immunol 16, 1709-1719 (2009)
3. M Sela, E Mozes: Therapeutic vaccines in autoimmunity. Proc Natl Acad Sci USA 101, 14586-14592 (2004) (Pubitemid 39346728)
4. RR Beerli, M Bauer, N Schmitz, RB Buser, M Gwerder, S Muntwiler, WA Renner, P Saudan, MF Bachmann: Prophylactic and therapeutic activity of fully human monoclonal antibodies directed against influenza A M2 protein. Virol J 6, 224 (2009)
5. MM Davis: A prescription for human immunology. Immunity 29, 835-838 (2008)
6. RN Germain: Vaccines and the future of human immunology. Immunity 33, 441-450 (2010)
7. L Mariani, A Venuti: HPV vaccine: an overview of immune response, clinical protection, and new approaches for the future. J Transl Med 8, 105 (2010)
8. RF Edlich, LG Hill, CA Mahler, MJ Cox, DG Becker, JH Horowitz, LS Nichter, ML Martin, WC Lineweaver: Management and prevention of tetanus. J Long Term Eff Med Implants 13, 139-154 (2003) (Pubitemid 36807804)
9. RC Kankonkar, DG Kulkurni, CB Hulikavi: Preparation of a potent anti-scorpion-venom-serum against the venom of red scorpion (Buthus tamalus). J Postgrad Med 44, 85-92 (1998) (Pubitemid 128526334)
10. CE Griffiths, BE Strober, P van de Kerkhof, V Ho, R Fidelus-Gort, N Yeilding, C Guzzo, Y Xia, B Zhou, S Li, LT Dooley, NH Goldstein, A Menter, ACCEPT Study Group: Comparison of ustekinumab and etanercept for moderate-Tosevere psoriasis. N Engl J Med 362, 118-128 (2010)
11. I Lowy, DC Molrine, BA Leav, BM Blair, R Baxter, DN Gerding, G Nichol, WD Jr. Thomas, M Leney, S Sloan, CA Hay, DM Ambrosino: Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 362, 197-205 (2010)
12. R Deng, S Iyer, FP Theil, DL Mortensen, PJ Fielder, S Prabhu: Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: What have we learned? MAbs 3, 61-66 (2011)
13. H Bernhard, L Salazar, K Schiffman, A Smorlesi, B Schmidt, KL Knutson, ML Disis: Vaccination against the HER-2/neu oncogenic protein. Endocr Relat Cancer 9, 33-44 (2002) (Pubitemid 34298362)
14. LM Walker, DR Burton: Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Curr Opin Immunol 22, 358-366 (2010)
15. AL Nelson, E Dhimolea, JM Reichert: Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 9, 767-774 (2010)
16. RL Ferris, EM Jaffee, S Ferrone: Tumor antigen-Targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J Clin Oncol 28, 4390-4399 (2010)
17. P Klein Klouwenberg, L Bont: Neonatal and infantile immune responses to encapsulated bacteria and conjugate vaccines. Clin Dev Immunol 2008, 628963 (2008)
18. AS Lauring, JON Jones, R Andino: Rationalizing the development of live attenuated virus vaccines. Nat Biotechnol 28, 573-579 (2010)
19. R Curtiss: Bacterial infectious disease control by vaccine development. J Clin Invest 110, 1061-1066 (2002)
20. RT Evans, B Klausen, HT Sojar, GS Bedi, C Sfintescu, NS Ramamurthy, LM Golub, RJ Genco: Immunization with Porphyromonas (Bacteroides) gingivalis fimbriae protects against periodontal destruction. Infect Immun 60, 2926-2935 (1992)
21. GD Healey, SJ Elvin, M Morton, ED Williamson: Humoral and cell-mediated adaptive immune responses are required for protection against Burkholderia pseudomallei challenge and bacterial clearance postinfection. Infect Immun 73, 5945-5951 (2005) (Pubitemid 41193033)
22. G Szalay, CH Ladel, SH Kaufmann: Stimulation of protective CD8+ T lymphocytes by vaccination with nonliving bacteria. Proc Natl Acad Sci U S A 92, 12389-12392 (1995) (Pubitemid 26014075)
23. DG Moriel, M Scarselli, L Serino, M Mora, R Rappuoli, V Masignani: Genome-based vaccine development: a short cut for the future. Hum Vaccin 4, 184-188 (2008)
24. CD Rinaudo, JL Telford, R Rappuoli, KL Seib: Vaccinology in the genome era. J Clin Invest 119, 2515-2525 (2009)
25. I de Filippis: Quest for a broad-range vaccine against Neisseria meningitidis serogroup B: implications of genetic variations of the surface-exposed proteins. J Med Microbiol 58, 1127-1132 (2009)
26. W Liu, T Meckel, P Tolar, HW Sohn, SK Pierce: Antigen affinity discrimination is an intrinsic function of the B cell receptor. J Exp Med 207, 1095-1111 (2010)
27. JM Kel, B Slutter, JW Drijfhout, F Koning, L Nagelkerken: Mannosylated self-peptide inhibits the development of experimental autoimmune encephalomyelitis via expansion of nonencephalitogenic T cells. J Leukoc Biol 84, 182-190 (2008) (Pubitemid 351960293)
28. L Bruns, O Frey, L Morawietz, C Landgraf, R Volkmer, T Kamradt: Immunization with an immunodominant self-peptide derived from glucose-6-phosphate isomerase induces arthritis in DBA/1 mice. Arthritis Res Ther 11, R117 (2009)
29. OT Avery, WF Goebel: Chemo-Immunological studies on conjugated carbohydrate-proteins: II. Immunological specificity of synthetic sugar-protein antigens. J Exp Med 50, 533-550 (1929)
30. WF Goebel, OT Avery: Chemo-immunological studies on conjugated carbohydrate-proteins: I. the synthesis of p-Aminophenol beta-glucoside, paminophenol beta-galactoside, and their coupling with serum globulin. J Exp Med 50, 521-531 (1929)
31. KJ Doores, Z Fulton, V Hong, MK Patel, CN Scanlan, MR Wormald, MG Finn, DR Burton, IA Wilson, BG Davis: A nonself sugar mimic of the HIV glycan shield shows enhanced antigenicity. Proc Natl Acad Sci U S A 107, 17107-17112 (2010)
32. DF Kelly, ER Moxon, AJ Pollard: Haemophilus influenzae type b conjugate vaccines. Immunology 113, 163-174 (2004) (Pubitemid 39312443)
33. PH Makela, H Kayhty, T Leino, K Auranen, H Peltola, N Ekström, J Eskola: Long-Term persistence of immunity after immunisation with Haemophilus influenzae type b conjugate vaccine. Vaccine 22, 287-292 (2003) (Pubitemid 37412271)
34. G Barouta, M Karapetsa, E Kostopoulou, I Alexiou, G Koukoulis, LI Sakkas: Oral tuberculosis in a patient with rheumatoid arthritis after long treatment with methotrexate and adalimumab. J Clin Rheumatol 16, 330-331 (2010)
35. DR Getts, MT Getts, DP McCarthy, EM Chastain, SD Miller: Have we overestimated the benefit of human(ized) antibodies? MAbs 2, 682-694 (2010)
36. G D'Arena, L Laurenti, MM Minervini, S Deaglio, L Bonello, L De Martino, L De Padua, L Savino, M Tarnani, V De Feo, N Cascavilla: Regulatory T-cell number is increased in chronic lymphocytic leukemia patients and correlates with progressive disease. Leuk Res 35, 363-368 (2011)
37. JC Sun: Re-educating natural killer cells. J Exp Med 207, 2049-2052 (2010)
38. E Dotan, C Aggarwal, MR Smith: Impact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin's Lymphoma. P T 35, 148-157 (2010)
39. SM Ansell, SA Hurvitz, PA Koenig, BR LaPlant, BF Kabat, D Fernando, TM Habermann, DJ Inwards, M Verma, R Yamada, C Erlichman, I Lowy, JM Timmerman: Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res 15, 6446-6453 (2009)
40. GR Burmester, G Ferraccioli, RM Flipo, I Monteagudo-Sáez, K Unnebrink, S Kary, H Kupper: Clinical remission and/or minimal disease activity in patients receiving adalimumab treatment in a multinational, open-label, twelve-week study. Arthritis Rheum 59, 32-41 (2008) (Pubitemid 351171876)
41. W Hueber, DD Patel, T Dryja, AM Wright, I Koroleva, G Bruin, C Antoni, Z Draelos, MH, Psoriasis Study Group, P Durez, PP Tak, JJ Gomez-Reino, Rheumatoid Arthritis Study Group, CS Foster, RY Kim, CM Samson, NS Falk, DS Chu, D Callanan, QD Nguyen, Uveitis Study Group, K Rose, A Haider, F Di Padova: Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2, 52ra72 (2010)
42. EI Tuomanen, K Saukkonen, S Sande, C Cioffe, SD Wright: Reduction of inflammation, tissue damage, and mortality in bacterial meningitis in rabbits treated with monoclonal antibodies against adhesion-promoting receptors of leukocytes. J Exp Med 170, 959-969 (1989) (Pubitemid 19226676)
43. HJ Ko, YJ Kim, YS Kim, WS Chang, SY Ko, SY Chang, S Sakaguchi, CY Kang: A combination of chemoimmunotherapies can efficiently break self-Tolerance and induce antitumor immunity in a tolerogenic murine tumor model. Cancer Res 67, 7477-7486 (2007) (Pubitemid 47206577)
44. AC Tissot, P Maurer, J Nussberger, R Sabat, T Pfister, S Ignatenko, HD Volk, H Stocker, P Müller, GT Jennings, F Wagner, MF Bachmann: Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. Lancet 371, 821-827 (2008) (Pubitemid 351323893)
45. ML Disis: Enhancing cancer vaccine efficacy via modulation of the tumor microenvironment. Clin Cancer Res 15, 6476-6478 (2009)
46. M Terabe, E Ambrosino, S Takaku, JJ O'Konek, D Venzon, S Lonning, JM McPherson, JA Berzofsky: Synergistic enhancement of CD8+ T cell-mediated tumor vaccine efficacy by an anti-Transforming growth factorbeta monoclonal antibody. Clin Cancer Res 15, 6560-6569 (2009)
47. R Ueda, M Fujita, X Zhu, K Sasaki, ER Kastenhuber, G Kohanbash, HA McDonald, J Harper, S Lonning, H Okada: Systemic inhibition of transforming growth factorbeta in glioma-bearing mice improves the therapeutic efficacy of glioma-Associated antigen peptide vaccines. Clin Cancer Res 15, 6551-6559 (2009)
48. HL Spiegelberg, L Beck, HP Kocher, WC Fanslow, AH Lucas: Role of interleukin-4 in human immunoglobulin E formation in hu-PBL-SCID mice. J Clin Invest 93, 711-717 (1994) (Pubitemid 24072813)
49. CL Efferson, J Schickli, BK Ko, K Kawano, S Mouzi, P Palese, A García-Sastre, CG Ioannides: Activation of tumor antigen-specific cytotoxic T lymphocytes (CTLs) by human dendritic cells infected with an attenuated influenza A virus expressing a CTL epitope derived from the HER-2/neu proto-oncogene. J Virol 77, 7411-7424 (2003) (Pubitemid 36734510)
50. L Fong, D Brockstedt, C Benike, JK Breen, G Strang, CL Ruegg, EG Engleman: Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. J Immunol 167, 7150-7156 (2001) (Pubitemid 33144213)
51. EY Nikitina, S Chada, C Muro-Cacho, B Fang, R Zhang, JA Roth, DI Gabrilovich: An effective immunization and cancer treatment with activated dendritic cells transduced with full-length wild-Type p53. Gene Ther 9, 345-352 (2002) (Pubitemid 34285148)
52. F Okano, M Merad, K Furumoto, EG Engleman: In vivo manipulation of dendritic cells overcomes tolerance to unmodified tumor-Associated self antigens and induces potent antitumor immunity. J Immunol 174, 2645-2652 (2005) (Pubitemid 40279678)
53. TC Tzeng, JL Suen, BL Chiang: Dendritic cells pulsed with apoptotic cells activate self-reactive T-cells of lupus mice both in vitro and in vivo. Rheumatology 45, 1230-1237 (2006)
54. DJ Cole, S Gattoni-Celli, EF McClay, JS Metcalf, JM Brown, N Nabavi, DA Newton 3rd, CB Woolhiser, MC Wilson, JN Vournakis: Characterization of a sustainedrelease delivery system for combined cytokine/peptide vaccination using a poly-N-Acetyl glucosamine-based polymer matrix. Clin Cancer Res 3, 867-873 (1997) (Pubitemid 27252934)
55. WW Overwijk, MR Theoret, SE Finkelstein, DR Surman, LA de Jong, FA Vyth-Dreese, TA Dellemijn, PA Antony, PJ Spiess, DC Palmer, DM Heimann, CA Klebanoff, Z Yu, LN Hwang, L Feigenbaum, AM Kruisbeek, SA Rosenberg, NP Restifo: Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med 198, 569-580 (2003) (Pubitemid 37040391)
56. G Ragupathi, KS Yeung, PC Leung, M Lee, CB Lau, A Vickers, C Hood, G Deng, NK Cheung, B Cassileth, P Livingston: Evaluation of widely consumed botanicals as immunological adjuvants. Vaccine 26, 4860-4865 (2008)
57. RN Coler, SL Baldwin, N Shaverdian, S Bertholet, SJ Reed, VS Raman, X Lu, J DeVos, K Hancock, JM Katz, TS Vedvick, MS Duthie, CH Clegg, N Van Hoeven, SG Reed: A synthetic adjuvant to enhance and expand immune responses to influenza vaccines. PLoS One 5, e13677 (2010)
58. BS Graham, MJ McElrath, MC Keefer, K Rybczyk, D Berger, KJ Weinhold, J Ottinger, G Ferarri, DC Montefiori, D Stablein, C Smith, R Ginsberg, J Eldridge, A Duerr, P Fast, BF Haynes, AIDS Vaccine Evaluation Group: Immunization with cocktail of HIV-derived peptides in montanide ISA-51 is immunogenic, but causes sterile abscesses and unacceptable reactogenicity. PLoS One 5, e11995 (2010)
59. MH Huang, SC Lin, CH Hsiao, HJ Chao, HR Yang, CC Liao, PW Chuang, HP Wu, CY Huang, CH Leng, SJ Liu, HW Chen, AH Chou, AY Hu, P Chong: Emulsified nanoparticles containing inactivated influenza virus and CpG oligodeoxynucleotides critically influences the host immune responses in mice. PLoS One 5, e12279 (2010)
60. J Willers, A Lucchese, D Kanduc, S Ferrone: Molecular mimicry of phage displayed peptides mimicking GD3 ganglioside. Peptides 20, 1021-1026 (1999) (Pubitemid 29424207)
61. A Mittelman, R Tiwari, G Lucchese, J Willers, R Dummer, D Kanduc: Identification of monoclonal anti-HMW-MAA antibody linear peptide epitope by proteomic database mining. J Invest Dermatol 123, 670-675 (2004) (Pubitemid 39281607)
62. R Dummer, A Mittelman, FP Fanizzi, G Lucchese, J Willers, D Kanduc: Non-self-discrimination as a driving concept in the identification of an immunodominant HMW-MAA epitopic peptide sequence by autoAbs from melanoma cancer patients. Int J Cancer 111, 720-726 (2004) (Pubitemid 39062894)
63. A Lucchese, J Willers, A Mittelman, D Kanduc, R Dummer: Proteomic scan for tyrosinase peptide antigenic pattern in vitiligo and melanoma: role of sequence similarity and HLA-DR1 affinity. J Immunol 175, 7009-7020 (2005) (Pubitemid 41598948)
64. J Willers, A Lucchese, A Mittelman, R Dummer, D Kanduc: Definition of anti-Tyrosinase MAb T311 linear determinant by proteome-based similarity analysis. Exp Dermatol 14, 543-550 (2005) (Pubitemid 40883413)
65. D Kanduc: Immunogenicity in peptideimmunotherapy: from self/nonself to similar/dissimilar sequences. Adv Exp Med Biol 640, 198-207 (2008)
66. D Kanduc, G Novello, R Mazzanti: P-170 peptides with low similarity to the human proteome: tracing an effective and safe biological way towards effective and safe cancer chemotherapy. J Exp Ther Oncol 8, 151-155 (2009)
67. D Kanduc: The self/nonself issue: A confrontation between proteomes. Self Nonself 1, 255-258 (2010)
68. D Kanduc: Peptimmunology: immunogenic peptides and sequence redundancy. Curr Drug Discov Technol 2, 239-244 (2005) (Pubitemid 43168115)
69. D Kanduc: "Self-nonself" peptides in the design of vaccines. Curr Pharm Des 15, 3283-3289 (2009)
70. D Kanduc, A Lucchese, A Mittelman: Nonredundant peptidomes from DAPs: towards "the vaccine"? Autoimmun Rev 6, 290-294 (2007) (Pubitemid 46507994)
71. D Kanduc: Epitopic peptides with low similarity to the host proteome: towards biological therapies without side effects. Expert Opin Biol Ther 9, 45-53 (2009)
72. G Lucchese, A Stufano, D Kanduc: Proteomeguided search for influenza A B-cell epitopes. FEMS Immunol Med Microbiol 57, 88-92 (2009)
73. G Lucchese, A Stufano, D Kanduc: Proposing lowsimilarity peptide vaccines against Mycobacterium tuberculosis. J Biomed Biotechnol 2010, 832341 (2010)
74. G Lucchese, A Stufano A, D Kanduc: Searching for an effective, safe and universal anti-HIV vaccine: Finding the answer in just one short peptide. Self Nonself 2, 49-54 (2011)
75. G Angelini, D Bonamonte, A Lucchese, G Favia, R Serpico, A Mittelman, S Simone, AA Sinha, D Kanduc: Preliminary data on Pemphigus vulgaris treatment by a proteomics-defined peptide: a case report. J Transl Med 4, 43 (2006)
76. GP Smith: Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 228, 1315-1317 (1985) (Pubitemid 15000355)
77. AB Riemer, E Jensen-Jarolim: Mimotope vaccines: epitope mimics induce anti-cancer antibodies. Immunol Lett 113, 1-5 (2007) (Pubitemid 47495954)
78. D Kozbor: Cancer vaccine with mimotopes of tumorassociated carbohydrate antigens. Immunol Res 46, 23-31 (2010)
79. F Helling, A Shang, M Calves, S Zhang, S Ren, RK Yu, HF Oettgen, PO Livingston: GD3 vaccines for melanoma: superior immunogenicity of keyhole limpet hemocyanin conjugate vaccines. Cancer Res 54, 197-203 (1994)
80. R Lo-Man, S Vichier-Guerre, R Perraut, E Dériaud, V Huteau, L BenMohamed, OM Diop, PO Livingston, S Bay, C Leclerc: A fully synthetic therapeutic vaccine candidate targeting carcinoma-Associated Tn carbohydrate antigen induces tumor-specific antibodies in nonhuman primates. Cancer Res 64, 4987-4994 (2004) (Pubitemid 38924547)
81. DK Hatsukami, S Rennard, D Jorenby, M Fiore, J Koopmeiners, A de Vos, G Horwith, PR Pentel: Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. Clin Pharmacol Ther 78, 456-467 (2005) (Pubitemid 41698900)
82. B Chackerian, DR Lowy, JT Schiller: Conjugation of a self-Antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies. J Clin Invest 108, 415-423 (2001) (Pubitemid 32730788)
83. I Sonderegger, TA Rohn, MO Kurrer, G Iezzi, Y Zou, RA Kastelein, MF Bachmann, M Kopf: Neutralization of IL-17 by active vaccination inhibits IL-23-dependent autoimmune myocarditis. Eur J Immunol 36, 2849-2856 (2006) (Pubitemid 44782558)
84. G Spohn, R Guler, P Johansen, I Keller, M Jacobs, M Beck, F Rohner, M Bauer, K Dietmeier, TM Kündig, GT Jennings, F Brombacher, MF Bachmann: A virus-like particle-based vaccine selectively targeting soluble TNFalpha protects from arthritis without inducing reactivation of latent tuberculosis. J Immunol 178, 7450-7457 (2007) (Pubitemid 46847473)
85. G Spohn, I Keller, M Beck, P Grest, GT Jennings, MF Bachmann: Active immunization with IL-1 displayed on virus-like particles protects from autoimmune arthritis. Eur J Immunol 38, 877-887 (2008)
86. G Spohn, K Schwarz, P Maurer, H Illges, N Rajasekaran, Y Choi, GT Jennings, MF Bachmann: Protection against osteoporosis by active immunization with TRANCE/RANKL displayed on virus-like particles. J Immunol 175, 6211-6218 (2005) (Pubitemid 41508110)
87. J Cornuz, S Zwahlen, WF Jungi, J Osterwalder, K Klingler, G van Melle, Y Bangala, I Guessous, P Müller, J Willers, P Maurer, MF Bachmann, T Cerny: A vaccine against nicotine for smoking cessation: a randomized controlled trial. PLoS One 3, e2547 (2008)
88. DE Speiser, K Schwarz, P Baumgaertner, V Manolova, E Devevre, W Sterry, P Walden, A Zippelius, KB Conzett, G Senti, V Voelter, JP Cerottini, D Guggisberg, J Willers, C Geldhof, P Romero, T Kündig, A Knuth, R Dummer, U Trefzer, MF Bachmann: Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients. J Immunother 33, 848-858 (2010)
89. A Boasso, GM Shearer, M Clerici: The hunt for an HIV vaccine: time to rethink recent failures. Lancet 371, 1897-1898 (2008) (Pubitemid 351778175)
90. CR Andersson, S Vene, M Insulander, L Lindquist, A Lundkvist, G Günther: Vaccine failures after active immunisation against tick-borne encephalitis. Vaccine 28, 2827-2831 (2010)
91. J Cohen: Immunology. Painful failure of promising genital herpes vaccine. Science 330, 304 (2010)
92. JC Bailar 3rd, HL Gornik: Cancer undefeated. N Engl J Med 336, 1569-1574 (1997) (Pubitemid 27231159)
93. A Jemal, MJ Thun, LA Ries, HL Howe, HK Weir, MM Center, E Ward, XC Wu, C Eheman, R Anderson, UA Ajani, B Kohler, BK Edwards: Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 100, 1672-1694 (2008)
94. Ehrlich letter to Althoff, 1/1/1905, Rockefeller Archives Center, RAC Ehrlich Papers, box 10, file:"Briefe von Hedwig u. Paul Ehrlich an Friedrich Althoff," pp. 82-83 (1905)
95. AM Silverstein: Paul Ehrlich's Receptor Immunology: The Magnificent Obsession. Academic Press (2002)
96. S Markovic-Plese: Degenerate T-cell receptor recognition, autoreactive cells, and the autoimmune response in multiple sclerosis. Neuroscientist 15, 225-231 (2009)
97. C Mazza, B Malissen: What guides MHC-restricted TCR recognition? Semin Immunol 19, 225-235 (2007) (Pubitemid 47044975)
98. A Mittelman, G Lucchese, A Stufano, D Kanduc: Degenerate binding of tyrosinase peptides to MHC II Ad/Ed molecules. J Exp Ther Oncol 6, 231-239 (2007) (Pubitemid 46789723)
99. S Buus, A Sette, SM Colon, HM Grey: Autologous peptides constitutively occupy the antigen binding site on Ia. Science 242, 1045-1047 (1988)
100. DA Schmid, MB Irving, V Posevitz, M Hebeisen, A Posevitz-Fejfar, JC Sarria, R Gomez-Eerland, M Thome, TN Schumacher, P Romero, DE Speiser, V Zoete, O Michielin, N Rufer: Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function. J Immunol 184, 4936-4946 (2010)
101. CK Baumgartner, A Ferrante, M Nagaoka, J Gorski, LP Malherbe: Peptide-MHC class II complex stability governs CD4 T cell clonal selection. J Immunol 184, 573-581 (2010)
102. PV Praveen, R Yaneva, H Kalbacher, S Springer: Tapasin edits peptides on MHC class I molecules by accelerating peptide exchange. Eur J Immunol 40, 214-224 (2010)
103. RK Gupta, EH Relyveld, EB Lindblad, B Bizzini, S Ben-Efraim, CK Gupta: Adjuvants, a balance between toxicity and adjuvanticity. Vaccine 11, 293-306 (1993)
104. E Israeli, N Agmon-Levin, M Blank, Y Shoenfeld: Adjuvants and autoimmunity. Lupus 18, 1217-1225 (2009)
105. N Petrovsky: Freeing vaccine adjuvants from dangerous immunological dogma. Expert Rev Vaccines 7, 7-10 (2008) (Pubitemid 351359053)
106. D Kanduc: Describing the hexapeptide identity platform between the influenza A H5N1 and Homo sapiens proteomes. Biologics 4, 245-261 (2010)
107. B Trost, G Lucchese, A Stufano, M Bickis, A Kusalik, D Kanduc: No human protein is exempt from bacterial motifs, not even one. Self Nonself 1, 328-334 (2010)
108. G Lucchese, A Stufano, M Calabrò, D Kanduc: Charting the peptide crossreactome between HIV-1 and the human proteome. Front Biosci 3, 1385-1400 (2011)
109. D Kanduc: Peptide cross-reactivity: the original sin of vaccines. Front Biosci (2011) in press)
110. C Natale, T Giannini, A Lucchese, D Kanduc: Computer-Assisted analysis of molecular mimicry between human papillomavirus 16 E7 oncoprotein and human protein sequences. Immunol Cell Biol 78, 580-585 (2000)
111. D Kanduc: Quantifying the possible cross-reactivity risk of an HPV16 vaccine. J Exp Ther Oncol 8, 65-76 (2009)
112. A Kusalik, M Bickis, C Lewis, Y Li, G Lucchese, FM Marincola, D Kanduc: Widespread and ample peptide overlapping between HCV and Homo sapiens proteomes. Peptides 28, 1260-1267 (2007) (Pubitemid 46843388)
113. D Kanduc, A Stufano, G Lucchese, A Kusalik: Massive peptide sharing between viral and human proteomes. Peptides 29, 1755-1766 (2008)
114. R Ricco, D Kanduc: Hepatitis B virus and Homo sapiens proteome-wide analysis: A profusion of viral peptide overlaps in neuron-specific human proteins. Biologics 4, 75-81 (2010)
115. B Trost, A Kusalik, G Lucchese, D Kanduc: Bacterial peptides are intensively present throughout the human proteome. Self Nonself 1, 71-74 (2010)
116. SL Bavaro, D Kanduc: Pentapeptide commonality between Corynebacterium diphtheriae toxin and the Homo sapiens proteome. Immunotherapy 3, 49-58 (2011)
117. SL Bavaro, M Calabrò, D Kanduc: Pentapeptide sharing between Corynebacterium diphtheria toxin and the human neural protein network. Immunopharmacol Immunotoxicol 33, 360-372 (2011)
118. D Kanduc, G Capone, VP Delfino, G Losa: The fractal dimension of protein information. Adv Stud Biol 2, 53-62 (2010)
119. MW Cunningham, SM Antone, JM Gulizia, BM McManus, VA Fischetti, CJ Gauntt: Cytotoxic and viral neutralizing antibodies crossreact with streptococcal M protein, enteroviruses, and human cardiac myosin. Proc Natl Acad Sci U S A 89, 1320-1324 (1992)
120. KL Hardgrave, BR Neas, RH Scofield, JB Harley: Antibodies to vesicular stomatitis virus proteins in patients with systemic lupus erythematosus and in normal subjects. Arthritis Rheum 36, 962-970 (1993) (Pubitemid 23201111)
121. Z Yu, NP Restifo: Cancer vaccines: progress reveals new complexities. J Clin Invest 110, 289-294 (2002) (Pubitemid 34847958)
122. RR Caspi: Immunotherapy of autoimmunity and cancer: the penalty for success. Nat Rev Immunol 8, 970-976 (2008)
123. A Stufano, G Capone, B Pesetti, L Polimeno, D Kanduc: Clustering of rare peptide segments in the HCV immunome. Self Nonself 1, 154-162 (2010)
124. F Baggi, A Annoni, F Ubiali, M Milani, R Longhi, W Scaioli, F Cornelio, R Mantegazza, C Antozzi: Breakdown of tolerance to a self-peptide of acetylcholine receptor alpha-subunit induces experimental myasthenia gravis in rats. J Immunol 172, 2697-2703 (2004) (Pubitemid 38182422)
125. A Lernmark: Autoimmune diseases: are markers ready for prediction? J Clin Invest 108, 1091-1096 (2001) (Pubitemid 32995365)
126. B Ayoglu, A Häggmark, M Neiman, U Igel, M Uhlén, JM Schwenk, P Nilsson: Systematic antibody and antigen-based proteomic profiling with microarrays. Expert Rev Mol Diagn 11, 219-234 (2011)
127. JY Kim, JE Do, KJ Ahn, S Noh, HJ Jee, SH Oh: Detection of melanocyte autoantigens reacting with autoantibodies in vitiligo patients by proteomics. J Dermatol Sci 62, 202-204 (2011)
128. A Lucchese, A Mittelman, L Tessitore, R Serpico, AA Sinha, D Kanduc: Proteomic definition of a desmoglein linear determinant common to Pemphigus vulgaris and Pemphigus foliaceous. J Transl Med 4, 37 (2006)
129. L Polimeno, A Mittelman, L Gennero, A Ponzetto, G Lucchese, A Stufano, A Kusalik, D Kanduc: Sub-epitopic dissection of HCV E1315-328HRMAWDMMMNWSPT sequence by similarity analysis. Amino Acids 34, 479-484 (2008) (Pubitemid 351569757)
130. D Kanduc, R Serpico, A Lucchese, Y Shoenfeld: Correlating low-similarity peptide sequences and HIV Bcell epitopes. Autoimmun Rev 7, 291-296 (2008) (Pubitemid 351284547)
131. D Kanduc: Correlating low-similarity peptide sequences and allergenic epitopes. Curr Pharm Des 14, 289-295 (2008) (Pubitemid 351516873)
132. A Lucchese, R Serpico, V Crincoli, Y Shoenfeld, D Kanduc: Sequence uniqueness as a molecular signature of HIV-1-derived B-cell epitopes. Int J Immunopathol Pharmacol 22, 639-646 (2009)
133. A Stufano, D Kanduc: Proteome-based epitopic peptide scanning along PSA. Exp Mol Pathol 86, 36-40 (2009)
134. E Balasse, G Gatouillat, D Patigny, MC Andry, C Madoulet: In vivo anti-melanoma activities of the Melan-A/MART-1(101-115) T CD4+ cell peptide. Vaccine 27, 6107-6109 (2009)
135. M Tomita, K Tsumoto: Hybridoma technologies for antibody production. Immunotherapy 3, 371-380 (2011)
136. D Kanduc, A Lucchese, A Mittelman: Individuation of monoclonal anti-HPV16 E7 antibody linear peptide epitope by computational biology. Peptides 22, 1981-1985 (2001)
137. D Kanduc, FP Fanizzi, G Lucchese, S Stevanovic, AA Sinha, A Mittelman: NMR probing of in silico identification of anti-HPV16 E7 mAb linear peptide epitope. Peptides 25, 243-250 (2004) (Pubitemid 38520054)
138. A Lucchese, A Mittelman, MS Lin, D Kanduc, AA Sinha: Epitope definition by proteomic similarity analysis: identification of the linear determinant of the anti-Dsg3 MAb 5H10. J Transl Med 2, 43 (2004)